LB Pharma Presents NOVA-1 LB-102 Cognition Data at SIRS Society
27 Mar 2026 //
GLOBENEWSWIRE
LB Pharma Reveals 2025 Financials, Corporate Update
26 Mar 2026 //
GLOBENEWSWIRE
LB Pharma Starts Pivotal Ph 3 Trial of LB-102 in Schizophrenia
25 Mar 2026 //
GLOBENEWSWIRE
LB Pharma Appoints R&D Biotech Exec Dr. Robert Lenz To Board
09 Mar 2026 //
GLOBENEWSWIRE
LB Pharma Launches Phase 2 ILLUMINATE-1 Trial for LB-102
26 Jan 2026 //
GLOBENEWSWIRE
LB Pharma Included In Russell 2000 And Russell 3000 Indices
09 Dec 2025 //
GLOBENEWSWIRE
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress
06 Oct 2025 //
GLOBENEWSWIRE
LB Pharma Appoints William Kane And Rekha Hemrajani To Board
25 Sep 2025 //
GLOBENEWSWIRE

Market Place
Sourcing Support